口服Xa因子直接抑制剂阿哌沙班的临床研究进展(4)
[14] David G, Edward L, Mark AC. The new oral anticoagulants[J]. Blood, 2011, 115(1): 15-20.
[15] Graeme JH, John WE. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events[J]. Lancet Neurol, 2010, 9(3): 273-284.
[16] Luke RE, Gregory MP. New antithrombotics for atrial fibrillation[J]. Cardiovasc Ther, 2010, 28(5): 278-286.
[17] Renato DL, John HA, Sana MA ,et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale[J]. Am Heart J, 2010, 159(3): 331-339.
[18] APPRAISE?Steering Committee and Investigators,?Alexander JH,?Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial[J]. Circulation, 2009, 119(22): 2877-2885.
(收稿日期：2012-05-15), 百拇医药(王磊 钟静芬 时惠麟)
[15] Graeme JH, John WE. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events[J]. Lancet Neurol, 2010, 9(3): 273-284.
[16] Luke RE, Gregory MP. New antithrombotics for atrial fibrillation[J]. Cardiovasc Ther, 2010, 28(5): 278-286.
[17] Renato DL, John HA, Sana MA ,et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale[J]. Am Heart J, 2010, 159(3): 331-339.
[18] APPRAISE?Steering Committee and Investigators,?Alexander JH,?Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial[J]. Circulation, 2009, 119(22): 2877-2885.
(收稿日期：2012-05-15), 百拇医药(王磊 钟静芬 时惠麟)